Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Issue 3 (19th March 2015)

• Record Type: Journal Article
• Authors: Boukouris, Stephanie; Mathivanan, Suresh
• Other Names: Banks Roz guestEditor.; Lilley Kathryn guestEditor.; Speicher David W. guestEditor.
• Is Part Of: Proteomics. Volume 9:Issue 3/4(2015)
• Page Start: 358
• Page End: 367
• Publication Date: 2015-03-19
• Subjects: Biomarkers -- Bodily fluids -- Exosomes -- Extracellular vesicles -- Microvesicles; Proteomics -- Periodicals; 572.605
• DOI: 10.1002/prca.201400114
• Languages: English
• ISSNs: 1862-8346

Abstract

Abstract : Biomarkers are measurable indicators of a biological state. As our understanding of diseases meliorates, it is generally accepted that early diagnosis renders the best chance to cure a disease. In the context of proteomics, the discovery phase of identifying bonafide biomarkers and the ensuing validation phase involving large cohort of patient samples are impeded by the complexity of bodily fluid samples. High abundant proteins found in blood plasma make it difficult for the detection of low abundant proteins that may be potential biomarkers. Extracellular vesicles (EVs) have reignited interest in the field of biomarker discovery. EVs contain a tissue‐type signature wherein a rich cargo of proteins and RNA are selectively packaged. In addition, as EVs are membranous structures, the luminal contents are protected from degradation by extracellular proteases and are highly stable in storage conditions. Interestingly, an appealing feature of EV‐based biomarker analysis is the significant reduction in the sample complexity compared to whole bodily fluids. With these prescribed attributes, which are the rate‐limiting factors of traditional biomarker analysis, there is immense potential for the use of EVs for biomarker detection in clinical settings. This review will discuss the current issues with biomarker analysis and the potential use of EVs as reservoirs of disease biomarkers.